Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1014 RayzeBio
BioCentury & Getty Images

Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

RayzeBio combines the tumor-killing of actinium 225 with the target affinity and PK of macrocycles

RayzeBio is combining the tumor-killing potency of actinium 225 with the target affinity and PK of macrocycles.

Oct 15, 2020 | 1:02 AM GMT

RayzeBio thinks its targeting and radioisotope strategies can take radiopharmaceuticals from  a series of individual success stories to a broadly applicable platform technology for cancer.

The company

Read the full 784 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE